Peter Sheehan
Victoria University, Australia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Sheehan.
The Lancet | 2017
Peter Sheehan; Kim Sweeny; Bruce Rasmussen; Annababette Wils; Howard Friedman; Jacqueline Mahon; George C Patton; Susan M Sawyer; Eric Howard; John Symons; Karin Stenberg; Satvika Chalasani; Neelam Maharaj; Nicola J. Reavley; Hui Shi; Masha Fridman; Alison Welsh; Emeka Nsofor; Laura Laski
Investment in the capabilities of the worlds 1·2 billion adolescents is vital to the UNs Sustainable Development Agenda. We examined investments in countries of low income, lower-middle income, and upper-middle income covering the majority of these adolescents globally to derive estimates of investment returns given existing knowledge. The costs and effects of the interventions were estimated by adapting existing models and by extending methods to create new modelling tools. Benefits were valued in terms of increased gross domestic product and averted social costs. The initial analysis showed high returns for the modelled interventions, with substantial variation between countries and with returns generally higher in low-income countries than in countries of lower-middle and upper-middle income. For interventions targeting physical, mental, and sexual health (including a human papilloma virus programme), an investment of US
The Lancet | 2014
Karin Stenberg; Henrik Axelson; Peter Sheehan; Ian Anderson; A Metin Gülmezoglu; Marleen Temmerman; Elizabeth Mason; Howard S. Friedman; Zulfiqar A. Bhutta; Joy E Lawn; Kim Sweeny; Jim Tulloch; Peter M. Hansen; Mickey Chopra; Anuradha Gupta; Joshua P Vogel; Mikael Ostergren; Bruce Rasmussen; Carol Levin; Colin F. Boyle; Shyama Kuruvilla; Marjorie Koblinsky; Neff Walker; Andres de Francisco; Nebojsa Novcic; Carole Presern; Dean T. Jamison; Flavia Bustreo
4·6 per capita each year from 2015 to 2030 had an unweighted mean benefit to cost ratio (BCR) of more than 10·0, whereas, for interventions targeting road traffic injuries, a BCR of 5·9 (95% CI 5·8-6·0) was achieved on investment of
The Lancet Psychiatry | 2016
Dan Chisholm; Kim Sweeny; Peter Sheehan; Bruce Rasmussen; Filip Smit; Pim Cuijpers; Shekhar Saxena
0·6 per capita each year. Interventions to reduce child marriage (
Economic Analysis and Policy | 2009
John Houghton; Peter Sheehan
3·8 per capita each year) had a mean BCR of 5·7 (95% CI 5·3-6·1), with the effect high in low-income countries. Investment to increase the extent and quality of secondary schooling is vital but will be more expensive than other interventions-investment of
Australian Economic Review | 2013
Peter Sheehan; Robert Gregory
22·6 per capita each year from 2015 to 2030 generated a mean BCR of 11·8 (95% CI 11·6-12·0). Investments in health and education will not only transform the lives of adolescents in resource-poor settings, but will also generate high economic and social returns. These returns were robust to substantial variation in assumptions. Although the knowledge base on the impacts of interventions is limited in many areas, and a major research effort is needed to build a more complete investment framework, these analyses suggest that comprehensive investments in adolescent health and wellbeing should be given high priority in national and international policy.
Archive | 2008
Peter Sheehan
A new Global Investment Framework for Womens and Childrens Health demonstrates how investment in womens and childrens health will secure high health, social, and economic returns. We costed health systems strengthening and six investment packages for: maternal and newborn health, child health, immunisation, family planning, HIV/AIDS, and malaria. Nutrition is a cross-cutting theme. We then used simulation modelling to estimate the health and socioeconomic returns of these investments. Increasing health expenditure by just
Nature | 2018
George C Patton; Craig A. Olsson; Vegard Skirbekk; Richard Saffery; Mary E. Wlodek; Peter Azzopardi; Marcin Stonawski; Bruce Rasmussen; Elizabeth Spry; Kate L. Francis; Zulfiqar A. Bhutta; Nicholas J Kassebaum; Ali H. Mokdad; Christopher J L Murray; Andrew M. Prentice; Nicola J. Reavley; Peter Sheehan; Kim Sweeny; Russell M. Viner; Susan M Sawyer
5 per person per year up to 2035 in 74 high-burden countries could yield up to nine times that value in economic and social benefits. These returns include greater gross domestic product (GDP) growth through improved productivity, and prevention of the needless deaths of 147 million children, 32 million stillbirths, and 5 million women by 2035. These gains could be achieved by an additional investment of
The Lancet | 2018
Melanie Bertram; Kim Sweeny; Jeremy A. Lauer; Dan Chisholm; Peter Sheehan; Bruce Rasmussen; Senendra Raj Upreti; Lonim Prasai Dixit; Kenneth George; Samuel Deane
30 billion per year, equivalent to a 2% increase above current spending.
International Journal of Environment and Pollution | 2014
Sardar M. N. Islam; Peter Sheehan; Jim Gigas; Hieu Trinh; Fred Puno
BACKGROUND Depression and anxiety disorders are highly prevalent and disabling disorders, which result not only in an enormous amount of human misery and lost health, but also lost economic output. Here we propose a global investment case for a scaled-up response to the public health and economic burden of depression and anxiety disorders. METHODS In this global return on investment analysis, we used the mental health module of the OneHealth tool to calculate treatment costs and health outcomes in 36 countries between 2016 and 2030. We assumed a linear increase in treatment coverage. We factored in a modest improvement of 5% in both the ability to work and productivity at work as a result of treatment, subsequently mapped to the prevailing rates of labour participation and gross domestic product (GDP) per worker in each country. FINDINGS The net present value of investment needed over the period 2016-30 to substantially scale up effective treatment coverage for depression and anxiety disorders is estimated to be US
The Lancet Psychiatry | 2016
Dan Chisholm; Kim Sweeny; Peter Sheehan; Bruce Rasmussen; Filip Smit; Pim Cuijpers; Shekhar Saxena
147 billion. The expected returns to this investment are also substantial. In terms of health impact, scaled-up treatment leads to 43 million extra years of healthy life over the scale-up period. Placing an economic value on these healthy life-years produces a net present value of